Kodiak Completes Enrollment in Phase I study of KSI-301 in Diabetic Retinopathy

September 7, 2018: By Joan McKenna

Kodiak Sciences has completed enrollment in its Phase I study of KSI-301 in patients with diabetic retinopathy, the Palo Alto, California, company reported Aug. 31.

KSI-301 is an anti-VEGF biological agent designed to have an extended durability profile. Kodiak also plans to develop the retinal candidate for wet age-related macular degeneration.

The company said the drug has been safe and well tolerated in all subjects with no signs of ocular inflammation or drug-related adverse events at any dose.

The first patient was dosed by Pravin Dugel, MD, of Retinal Consultants of Arizona. Other patients were dosed by participating investigators Sunil Patel, MD, David Boyer, MD, and Richard McDonald, MD.

KSI-301 uses the company’s Antibody Biopolymer Conjugate, or ABC, platform, described as a merging the fields of antibody-based and chemistry-based therapies.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales